Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2- Advanced/Metastatic Breast Cancer Receiving CDK4/6i + Aromatase Inhibitor (AI) Combination Therapy as Initial Endocrine-based Treatment

NCT04396626 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04396626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04396626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2- Advanced/Metastatic Breast Cancer Receiving CDK4/6i + Aromatase Inhibitor (AI) Combination Therapy as Initial Endocrine-based Treatment
Lead sponsor
Pfizer
Phase
Observational
Overall status
Terminated
Start date
November 18, 2019
Completion date
May 31, 2020
Enrollment
975 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer